Biogen, Eisai’s lecanemab gets Alzheimer’s nod, but how successful it will be is uncertain Posted on January 7, 2023 By Charlielikes Stock Market
Biogen’s lecanemab shows less cognitive decline with Alzheimer’s, but more brain swelling Posted on November 30, 2022 By Charlielikes Stock Market
Biogen, Eisai Alzheimer’s candidate lecanemab meets primary endpoint in late-stage trial Posted on September 28, 2022 By Charlielikes Stock Market